Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Leukemia, Myeloid, Acute 9Lymphoma, Mantle-Cell 8Breast Neoplasms 7Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Recurrence 4Neuroblastoma 4Myelodysplastic Syndromes 4Mycosis Fungoides 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Leukemia 4Congenital Abnormalities 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Glioblastoma 3Burkitt Lymphoma 3

Interventions

Ipilimumab 10pembrolizumab 7Nivolumab 7incomplete Freund's adjuvant 6Temozolomide 5Dacarbazine 5tebentafusp 4Sunitinib 4MART-1 Antigen 4Carboplatin 4CTLA-4 Antigen 4sargramostim 3montanide ISA 51 3aflibercept 3Paclitaxel 3Bevacizumab 3trametinib 2relatlimab 2olaparib 2lenvatinib 2cediranib 2Vorinostat 2Thalidomide 2Taxes 2Sorafenib 2Radiosurgery 2MAGEA3 protein, human 2Lenalidomide 2Interleukin-2 2Interleukin-12 Subunit p35 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Uveal Melanoma × Vorinostat × Clear all
NCT01587352 2026-04-13

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Dermatologic

Uveal Melanoma

NCT00121225 2019-01-29

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
32 enrolled 11 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡